BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND SDHD, PGL1, 6392, ENSG00000204370, PGL, SDH4, CBT1, O14521 AND Clinical Outcome
8 results:

  • 1. The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
    Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B
    BMC Cancer; 2021 Mar; 21(1):234. PubMed ID: 33676450
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
    Yamazaki Y; Gao X; Pecori A; Nakamura Y; Tezuka Y; Omata K; Ono Y; Morimoto R; Satoh F; Sasano H
    Front Endocrinol (Lausanne); 2020; 11():587769. PubMed ID: 33193100
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Positive Impact of Genetic Test on the Management and outcome of Patients With Paraganglioma and/or Pheochromocytoma.
    Buffet A; Ben Aim L; Leboulleux S; Drui D; Vezzosi D; Libé R; Ajzenberg C; Bernardeschi D; Cariou B; Chabolle F; Chabre O; Darrouzet V; Delemer B; Desailloud R; Goichot B; Esvant A; Offredo L; Herman P; Laboureau S; Lefebvre H; Pierre P; Raingeard I; Reznik Y; Sadoul JL; Hadoux J; Tabarin A; Tauveron I; Zenaty D; Favier J; Bertherat J; Baudin E; Amar L; Gimenez-Roqueplo AP;
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1109-1118. PubMed ID: 30698717
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Immediate clinical Success After Percutaneous Ablation of Extra-adrenal Paraganglioma.
    Ierardi AM; Biondetti P; Ferrante G; Carugo S; Carrafiello G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1803-1806. PubMed ID: 29922859
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.
    Gupta S; Zhang J; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):269-275. PubMed ID: 28752484
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster.
    Fliedner SM; Shankavaram U; Marzouca G; Elkahloun A; Jochmanova I; Daerr R; Linehan WM; Timmers H; Tischler AS; Papaspyrou K; Brieger J; de Krijger R; Breza J; Eisenhofer G; Zhuang Z; Lehnert H; Pacak K
    Neoplasia; 2016 Sep; 18(9):567-76. PubMed ID: 27659016
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas.
    Oudijk L; van Nederveen F; Badoual C; Tissier F; Tischler AS; Smid M; Gaal J; Lepoutre-Lussey C; Gimenez-Roqueplo AP; Dinjens WN; Korpershoek E; de Krijger R; Favier J
    PLoS One; 2015; 10(3):e0121361. PubMed ID: 25794004
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
    Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
    BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.